Product Description
Dexmethylphenidate is used to treat attention deficit hyperactivity disorder (ADHD). It belongs to the group of medicines called central nervous system (CNS) stimulants. Dexmethylphenidate increases attention and decreases restlessness in patients who are hyperactive, cannot concentrate, or are easily distracted. (Sourced from: https://www.google.com/search?client=safari&rls=en&q=dexmethylphenidate&ie=UTF-8&oe=UTF-8)
Mechanisms of Action: NRI Inhibitor,DRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Chile | Israel | Pakistan | Switzerland | United Kingdom | United States
Approved Indications: Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity
Known Adverse Events: Abdominal Pain | Pain Unspecified | Anorexia | Headache | Dyspepsia | Tachycardia | Dizziness | Insomnia
Company: Cingulate Therapeutics
Company Location:
Company CEO: Shane J. Schaffer
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Attention Deficit Disorder with Hyperactivity
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Dexmethylphenidate | P3 |
Suspended |
Attention Deficit Disorder with Hyperactivity |
2026-08-01 |
|
| AK0901-2001 | P3 |
Not yet recruiting |
Attention Deficit Disorder with Hyperactivity |
2024-09-01 |
|
| Dexmethylphenidate | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2023-06-13 |
83% |
| Fed-Fast | P1 |
Completed |
Healthy Volunteers |
2022-10-14 |
70% |